Nexstim initiated with a BUY rating by NuWays AG
Original-research coverage from NuWays AG rates Nexstim as BUY, per a TradingView News dissemination.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.